(I-Newswire) December 7, 2009 - CEO and founder, James R. Berenson, MD and IMBCR researchers will present the following 9 papers, oral presentations and special sessions December 5-8, 2009 at the 51st ASH Annual Meeting and Exposition.
3050; Pleiotrophin Is Highly Produced by Solid Tumors and Transdifferentiates Human Monocytes Into Endothelial Cells
Eric Wirtschafter1*, Emily Wong1*, Mingjie Li1*, Eric Sanchez1*, Cathy S Wang1*, Jennifer Li1*, Riley Kessler1*, Mengyin Hu1*, Crystal Leung1*, Zhi-Wei Li, PhD1, Haiming Chen, MD, PhD1, Benjamin Bonavida, PhD2 and James R. Berenson, MD1
1Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
2Microbiology, Immunology & Molecular Genetics, University of CA, Los Angeles, Los Angeles, CA
611; TRAF6-Dominant Negative Peptides Show Potent Inhibitory Effects On Multiple Myeloma, Osteoclast Formation and Bone Resorption
Mingjie Li1*, Eric Sanchez1*, Jennifer Li1*, Cathy S Wang1*, Jing Shen1*, Mengyin Hu1*, Crystal Leung1*, Jessica Wang1*, Emily Wong1*, Anoushka Adler1*, Zhi-Wei Li, PhD1, Haiming Chen, MD, PhD1, Benjamin Bonavida, PhD2 and James R. Berenson, MD1
1Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
2Microbiology, Immunology & Molecular Genetics, University of CA, Los Angeles, Los Angeles, CA
1855; A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM)
James R. Berenson, MD1, Ori Yellin, MD2*, Ralph V. Boccia, MD3*, Youram Nassir, MD4*, Shellie Rothstein5* and Regina A. Swift4*
1Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
2Oncotherapeutics, West Hollywood, CA
3Center for Cancer and Blood Disorders, Bethesda, MD
4James R. Berenson, MD, Inc., West Hollywood, CA
5Novartis Pharmaceuticals Corporation, East Hanover, NJ
1840; Oral Dosing of the Novel Proteasome Inhibitor CEP-18770 Shows Marked Anti-Myeloma Effects in SCID-Hu Models of Multiple Myeloma
Eric Sanchez1*, Mingjie Li1*, Jeffrey A Steinberg1*, Cathy S Wang1*, Jing Shen1*, Benjamin Bonavida, PhD2, Zhi-Wei Li, PhD1, Haiming Chen, MD, PhD1 and James R. Berenson, MD1
1Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
2Microbiology, Immunology & Molecular Genetics, University of CA, Los Angeles, Los Angeles, CA
1932; Inverse Relationship Between the Transcription Repressor Yin Yang 1 (YY1) and the TRAIL Death Receptor DR5 in
AIDS-Related Non-Hodgkin’s Lymphoma Tissues: Potential Prognostic Biomarkers and Targets for Therapeutic Intervention
Sara Huerta-Yepez, PhD.1*, Mario I. Vega, PhD2, Clara Rivera-Pazos, MD3*, Otoniel Martinez-Maza, Ph.D.4*, James R. Berenson, MD5 and Benjamin Bonavida, PhD6
1Unidad de Investigacion en Enfermedades Oncologicas,, Hospital Infantil de Mexico, Federico Gomez, SSA, Mexico, Mexico City, Mexico
2Hosp. de Infect., CMN La Raza IMSS, Mexico, DF, Mexico
3Unidad de Investigacion en Enfermedades Oncologicas, Hospital Infantil de Mexico, Federico Gomez, SSA, Mexico, Mexico City, Mexico
4Obstetrics and Gynecology, University of California, Los Angeles, Los Angeles, CA
5Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
6Microbiology, Immunology & Molecular Genetics, University of CA, Los Angeles, Los Angeles, CA
3050; Pleiotrophin Is Highly Produced by Solid Tumors and Transdifferentiates Human Monocytes Into Endothelial Cells
Eric Wirtschafter1*, Emily Wong1*, Mingjie Li1*, Eric Sanchez1*, Cathy S Wang1*, Jennifer Li1*, Riley Kessler1*, Mengyin Hu1*, Crystal Leung1*, Zhi-Wei Li, PhD1, Haiming Chen, MD, PhD1, Benjamin Bonavida, PhD2 and James R. Berenson, MD1
1Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
2Microbiology, Immunology & Molecular Genetics, University of CA, Los Angeles, Los Angeles, CA
3832; Alpha Lipoic Acid (ALA) Inhibits the Anti-Myeloma Effects of Bortezomib
Jeffrey A Steinberg1*, Jing Shen1*, Eric Sanchez1*, Haiming Chen, MD, PhD1, Zhi-Wei Li, PhD1, Jacqueline Hilger, MS2* and James R. Berenson, MD1
1Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
2Millennium Pharmaceuticals, Inc., Cambridge, MA
3844; Pterostilbene: A Novel Histone Deacetylase 1 Inhibitor (HDACi1) Demonstrating Efficacy in Multiple Myeloma
Haiming Chen, MD, PhD1, Rui Hao, PhD2*, Eric Sanchez1*, Jing Shen1*, Mingjie Li1*, Jessica Wang1*, Emily Wong1*, Anoushka Adler1*, Mengyin Hu1*, Crystal Leung1*, Cathy S Wang1*, Zhi-Wei Li, PhD1, Benjamin Bonavida, PhD2 and James R. Berenson, MD1
1Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
2Microbiology, Immunology & Molecular Genetics, University of CA, Los Angeles, Los Angeles, CA
Inhibition of the RKIP and PTEN-Transcription Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis
Stavroula Baritaki1*, Kam Yeung, Ph.D.2*, Katherine Wu3*, Haiming Chen, MD, PhD4, James R. Berenson, MD5, Michael A. Palladino, PhD6 and Benjamin Bonavida, PhD7
1Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA
2Biochemistry and Molecular Biology, Medical College of Ohio, Toledo, OH
3Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA
4Hematology/Oncology, Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
5Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
6Nereus Pharmaceuticals, Inc., San Diego, CA
7Microbiology, Immunology & Molecular Genetics, University of CA, Los Angeles, Los Angeles, CA
About IMBCR The Institute for Myeloma and Bone Cancer Research is a non-profit organization headquartered in Los Angeles, California. IMBCR is the only independent cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma, a cancer of the blood cells that reside in the bone marrow.
IMBCR research has been published in most major oncology journals; Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Cancer, Clinical Cancer Research, Clinical Lymphoma and Myeloma, Oncogene, and the British Journal of Haematology. www.imbcr.org
About Institute for Myeloma and Bone Cancer Research:
The Institute for Myeloma and Bone Cancer Research is a non-profit organization headquartered in Los Angeles, California. IMBCR is the only independent cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma, a cancer of the blood cells that reside in the bone marrow.
Company Contact Information
Institute for Myeloma and Bone Cancer Research
Cheryl A. Cross
9201 Sunset Blvd.,
Suite 300
90069
Phone : 310-406-1035
|
